Piramal Enterprises’ Pharma Solutions division has conducted a review of the injectables market for both sterile and small molecule for the next five years in its CPhI annual report.   The review indicates that the near-term growth prospects are highest across generics, small molecule injectables, and in contract services. Vivek Sharma, chief executive officer, Pharma Solutions, Piramal Enterprises, said, “We recently acquired Coldstream in Kentucky, USA, to enhance our sterile injectabl...